Commit Biologics announced a $60 million seed financing to advance complement-powered immune engagers toward the clinic. The company plans to push COM002 through IND-enabling work with first patient dosing expected in early 2028 and to move a second program into IND-enabling development. Commit’s platform, described as complement-directed bispecific complement engager (BiCE) technology, aims to deplete targeted pathogenic immune cells implicated across both cancer and autoimmune disease. The financing was led by Ackermans & van Haaren, with AbbVie Ventures and M Ventures among new investors. For early-stage investors and strategic partners, the deal signals that complement engagement remains a funded path for immune-therapy modality diversification beyond checkpoint blockade.